M
M. E. van Linde
Researcher at VU University Amsterdam
Publications - 10
Citations - 211
M. E. van Linde is an academic researcher from VU University Amsterdam. The author has contributed to research in topics: Glioma & Temozolomide. The author has an hindex of 5, co-authored 10 publications receiving 138 citations. Previous affiliations of M. E. van Linde include VU University Medical Center.
Papers
More filters
Journal ArticleDOI
Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma
Joost J.C. Verhoeff,Cristina Lavini,M. E. van Linde,L. J. A. Stalpers,Charles B. L. M. Majoie,J.C. Reijneveld,W. R. van Furth,Dirk J. Richel +7 more
TL;DR: Treatment with bevacizumab and TMZ is feasible and well tolerated but did not improve PFS6 and median OS.
Journal Article
Treatment outcome of patients with recurrent glioblastoma multiforme
M. E. van Linde,Cyrillo G. Brahm,P. C. de Witt Hamer,Jaap C. Reijneveld,Anna M.E. Bruynzeel,Michiel Wagemakers,van der Hinke Weide,Roeline Enting,Hugo Verheul,Annemiek M E Walenkamp +9 more
TL;DR: In this paper, the efficacy of standard treatment strategies for patients with recurrent GBM (rGBM) was evaluated from two centers in the Netherlands, 299 patients with rGBM after first-line treatment, diagnosed between 2005 and 2014, were retrospectively evaluated.
Journal ArticleDOI
Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial
Gao Y,Bas Weenink,M. J. van den Bent,Lale Erdem-Eraslan,Johan M. Kros,P. A. E. Sillevis Smitt,Khê Hoang-Xuan,A. A. Brandes,Maaike J. Vos,F. Dhermain,Roelien H. Enting,Gail Ryan,Olivier Chinot,M. Ben Hassel,M. E. van Linde,Warren P. Mason,J.M.M. Gijtenbeek,Carmen Balana,A. von Deimling,Th Gorlia,Roger Stupp,Monika E. Hegi,Brigitta G. Baumert,Brigitta G. Baumert,Pim J. French +24 more
TL;DR: IGSs are prognostic for PFS in EORTC22033-26033 clinical trial samples, and it is shown that LGGs and glioblastomas differ in their immune infiltrate, which suggests that L GGs are less amenable to checkpoint inhibitor-type immune therapies.
Journal ArticleDOI
Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial
Nick Beije,Jan Kraan,Walter Taal,B. van der Holt,HM Oosterkamp,Annemiek M E Walenkamp,Laurens V. Beerepoot,Monique Hanse,M. E. van Linde,A. Otten,René M. Vernhout,F.Y.F.L. De Vos,Jan-Willem Gratama,Stefan Sleijfer,M. J. van den Bent +14 more
TL;DR: Although the absolute number of CECs was not associated with OS in patients treated with bevacizumab either alone or in combination, they could serve as a marker in glioblastoma patients receiving lomustine single agent.
Journal ArticleDOI
472pphase 1/2a study of glutathione pegylated liposomal doxorubicin (2b3-101) in patients with brain metastases (bm) from solid tumors or recurrent high grade gliomas (hgg)
Dieta Brandsma,B. Milojkovic Kerklaan,Véronique Diéras,Sevilay Altintas,Carey K. Anders,M. Arnedos Ballester,Hans Gelderblom,Patricia M. M. B. Soetekouw,Werner Gladdines,Fredrik Lonnqvist,Agnes Jager,M. E. van Linde,J.H.M. Schellens,Philippe Aftimos +13 more
TL;DR: 2B3-101 is safe and well tolerated and shows activity in advanced BCBM and HGG pts, diseases with limited treatment options, and warrant further randomized, controlled Phase 2b studies, with initial focus on (HER2+) BCBM.